Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
In a so-called real world study, the anti-coagulant did better in reducing the risk of strokes or major bleeds compared to warfarin than did J&J's competing Xarelto or Boehringer's&nb...
A federal court jury found that the companies did not mislead a Louisiana man and his doctors about the health risks of the Xarelto blood thinner.
MONDAY, March 20, 2017 -- Patients undergoing a surgical procedure to treat an irregular heartbeat are less likely to suffer problematic bleeding when given the blood thinner Pradaxa rather than warfa...
A supplemental new drug application has been filed by Janssen seeking to update the prescribing information for Xarelto, or r -More-
Data from a late-stage trial show that Bayer and Janssen’s Xarelto was better than aspirin at protecting patients from recurrent venous thromboembolism.
US payers may increasingly look to leverage the competition among the novel oral anticoagulants by contracting for preferred coverage with...
Janssen and Bayer have stopped a phase 3 trial of Xarelto early after results showed it can cut deaths, heart attacks and strokes compared to aspirin. The promising data paves the way for a lucrativ...
Bayer and Johnson & Johnson have won the first of around 18,000 lawsuits lawsuit being brought by US patients who claim the blood-thinning drug Xarelto caused their uncontrollable brain and gastro...
Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...